Literature DB >> 19082722

Severe refractory orofacial Crohn's disease: report of a case.

Sandra Quezada1, Patricia L Turner, Borislav Alexiev, Barry Daly, Raymond Cross.   

Abstract

Oral involvement is common in patients with Crohn's disease (CD) and can precede intestinal symptoms, making diagnosis difficult. We report a case of severe orofacial CD. A 41-year-old woman presented with palate and tongue ulcers. Biopsies showed acute inflammation with ulcer. Colonoscopy demonstrated ascending colon ulceration. Biopsies revealed acute colitis and mild architectural distortion. Prednisone was started but the symptoms recurred with taper; steroids were resumed and infliximab (IFX) 5 mg/kg was infused. After improvement, oral pain and weight loss returned. A G tube was placed. Mercaptopurine was started at 1.5 mg/kg per day. IFX was increased to 10 mg/kg. Debridement of the oral ulcers and a skin graft to the lips was performed. Pathology from oral and facial lesions was consistent with granulation tissue and fibrosis with chronic inflammation. She was readmitted several months later for weight loss and dehydration. Abdominal pain, distension, and feculent drainage developed around the G tube. Repeat computed tomography (CT) scan demonstrated pneumatosis. Laparotomy revealed purulent drainage from a perforated segment of sigmoid colon. Histology was consistent with perforated CD. Despite ventilatory and hemodynamic support and broad-spectrum antibiotics, the patient died 1 week later. Our case highlights the difficulty in diagnosing and managing orofacial CD. In this case, medical treatment was initiated based on a high index of suspicion. CD was only confirmed after intestinal resection very late in the disease course. Treatment of orofacial CD includes topical or systemic steroids, immunomodulators, and anti-tumor necrosis factor (TNF) therapies. As our case demonstrated, patients can be refractory to therapy.

Entities:  

Mesh:

Year:  2008        PMID: 19082722     DOI: 10.1007/s10620-008-0588-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Elemental diet in the treatment of orofacial Crohn's disease.

Authors:  E A B Cameron; S J Middleton
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 2.  Oral manifestations of Crohn's disease. An analysis of 79 cases.

Authors:  M Plauth; H Jenss; J Meyle
Journal:  J Clin Gastroenterol       Date:  1991-02       Impact factor: 3.062

3.  Oro-facial granulomatosis: Crohn's disease or a new inflammatory bowel disease?

Authors:  Jeremy Sanderson; Carlo Nunes; Michael Escudier; Kate Barnard; Penelope Shirlaw; Edward Odell; Catherine Chinyama; Stephen Challacombe
Journal:  Inflamm Bowel Dis       Date:  2005-09       Impact factor: 5.325

4.  Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease.

Authors:  A R Sánchez; R S Rogers; P J Sheridan
Journal:  J Oral Pathol Med       Date:  2005-01       Impact factor: 4.253

Review 5.  Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent.

Authors:  Thomas Bogenrieder; Gerhard Rogler; Thomas Vogt; Michael Landthaler; Wilhelm Stolz
Journal:  Dermatology       Date:  2003       Impact factor: 5.366

6.  Nasal septal perforation in an adolescent girl with Crohn's disease: a rare extraintestinal manifestation.

Authors:  Sinan Sari; Buket Dalgic; Metin Yilmaz; Aylar Poyraz
Journal:  Dig Dis Sci       Date:  2007-03-15       Impact factor: 3.199

7.  Melkerson Rosenthal syndrome.

Authors:  David L Hoexter
Journal:  N Y State Dent J       Date:  2007-03

8.  Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis.

Authors:  Anne Hegarty; Tim Hodgson; Stephen Porter
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2003-05

9.  The clinical entity of orofacial Crohn's disease.

Authors:  A J Williams; D Wray; A Ferguson
Journal:  Q J Med       Date:  1991-05

Review 10.  Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease.

Authors:  G Bens; D Laharie; M Beylot-Barry; B Vergier; I Noblesse; C Beylot; M Amouretti
Journal:  Br J Dermatol       Date:  2003-07       Impact factor: 9.302

View more
  4 in total

1.  Oral manifestation of Crohn's disease without concomitant gastrointestinal involvement.

Authors:  Hamid Salek; Amir Balouch; Parish P Sedghizadeh
Journal:  Odontology       Date:  2013-05-08       Impact factor: 2.634

Review 2.  Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview.

Authors:  Kyla Pagani; Danitza Lukac; Aashni Bhukhan; Jean S McGee
Journal:  Am J Clin Dermatol       Date:  2022-04-20       Impact factor: 6.233

3.  Skin manifestations of inflammatory bowel disease.

Authors:  Brian L Huang; Stephanie Chandra; David Quan Shih
Journal:  Front Physiol       Date:  2012-02-06       Impact factor: 4.566

Review 4.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.